Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $576.97, for a total transaction of $5,481,215.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at $23,374,785.61. This represents a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Trading Down 1.6%

Shares of NASDAQ:UTHR traded down $9.02 during trading on Tuesday, hitting $572.20. 560,802 shares of the stock were exchanged, compared to its average volume of 478,626. The company has a market cap of $25.08 billion, a PE ratio of 20.51, a P/E/G ratio of 1.62 and a beta of 0.60. The company has a fifty day moving average price of $543.83 and a two-hundred day moving average price of $498.27. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $607.89.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same period in the previous year, the firm posted $6.19 earnings per share. United Therapeutics’s revenue was up 7.4% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on UTHR shares. Royal Bank Of Canada lifted their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. UBS Group lifted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Raymond James Financial initiated coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $601.50.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its position in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the period. Darwin Global Management Ltd. purchased a new stake in United Therapeutics during the third quarter valued at about $317,617,000. Norges Bank acquired a new stake in United Therapeutics during the fourth quarter worth about $293,418,000. Avoro Capital Advisors LLC increased its stake in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.